Peptide News Digest

#Ozari-Health

2 stories

Industry · View digest

Ozari Health Launches Nationwide Compounded GLP-1 Telehealth Platform (May 19): Semaglutide $86/Month + Tirzepatide $120/Month, Hallandale + VialsRX Pharmacy Partners

Ozari Health, a New York-based telehealth company, launched a nationwide platform on Tuesday May 19, 2026 offering compounded semaglutide starting at $86/month and compounded tirzepatide starting at $120/month, with branded options (Wegovy, Ozempic, Mounjaro, Zepbound) available through the same channel. Patients complete an online intake, get evaluated by state-licensed providers, and receive prescriptions filled by partner compounding pharmacies including Hallandale Pharmacy and VialsRX — the multi-pharmacy partner structure differentiates Ozari from telehealth platforms that work with a single compounding partner. Ozari pricing sits at the floor of the compounded GLP-1 market; comparable platforms (Sesame, Henry Meds, Wisp) range $99-249/month for compounded semaglutide. The launch lands as the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (comments closing June 29) puts long-term compounding-pharmacy access in question.

Industry · View digest

Compounded GLP-1 Telehealth Pricing Floor Update — Ozari's $86/Month Semaglutide Anchors the Low End as 503B Bulks-List Comments Close June 29

Tuesday's Ozari Health launch at $86/month for compounded semaglutide and $120/month for compounded tirzepatide places the platform at the low end of the compounded GLP-1 telehealth pricing band. Comparable platforms in the same market: Sesame ~$99/month, Henry Meds $129-249/month, Wisp ~$199/month, Mochi Health $129/month introductory, MD Lifestyle $99-249/month. The pricing-floor compression is colliding with the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — comments close June 29, with the final determination expected late Q3 2026. If the FDA's 503B proposal stands, large-scale 503B compounding ends and platforms either shift to 503A pharmacies (lower volume, higher unit cost) or wind down. The current cohort of telehealth launches at $86-129/month likely represents the cheapest US compounded GLP-1 will be before the regulatory regime tightens. Branded Wegovy and Foundayo's $25-149/month commercial-insurance copays remain the lower-cost path for insured patients; the cash-pay compounded market is what these telehealth launches are competing for.